Talan.tech
AI Risk Check/IDEMIA MorphoFace
Other

IDEMIA MorphoFace

by IDEMIA

Face recognition deployed by US/EU governments. NIST bias study findings, civil-liberties scrutiny.

Relevant industries:Government

Risk Score: 1/100 (Low) · 1+ incidents · Legal 4 · Safety 0 · Privacy 0 · Regulatory 0 · Security 0

Risk Score

1/ 100
Low Risk

Apr 27, 2026

Risk Score Breakdown

Legal Risk

Court cases & lawsuits

4/100

Safety Risk

Incidents & harm events

0/100

Privacy Risk

Breaches & GDPR actions

0/100

Regulatory Risk

FTC, EU enforcement

0/100

Security Risk

CVEs & vulnerabilities

0/100

Incident Timeline

1 total incidents · showing 1 most recent

Mar 2021

CRITICALCourt CaseRESOLVED2:21-cv-04021
Court Case: PARKS v. MCCORMAC

A civil-rights lawsuit in the U.S. District Court for the District of New Jersey listed IDEMIA, Inc. (MorphoFace) among the parties in case 2:21-cv-04021. The case was terminated on 2024-07-09.

Court: District Court, D. New Jersey#courtlistener #lawsuit #court-case

Frequently Asked Questions

What is IDEMIA MorphoFace's AI risk score?

IDEMIA MorphoFace has an AI Risk Score of 1/100 (Low Risk). This score is calculated from 1+ documented public incidents across legal, safety, privacy, regulatory, and security categories.

Is IDEMIA MorphoFace safe to use?

IDEMIA MorphoFace by IDEMIA has a low risk profile based on public data. Organizations should review the full incident list and conduct their own due diligence. This score does not constitute legal advice.

Does IDEMIA MorphoFace have lawsuits?

Yes — our public records show 1 court case(s) for IDEMIA MorphoFace, including: Court Case: PARKS v. MCCORMAC.

How is the AI Risk Score calculated?

Scores are weighted across 5 categories: Legal (25%), Safety (25%), Privacy (20%), Regulatory (15%), Security (15%). Each incident is scored by severity and type, then decayed based on age. Active lawsuits and fatal incidents do not decay.

Stay ahead of AI risk

Get alerts when IDEMIA MorphoFace risk score changes

New lawsuits, breaches, and regulatory actions — delivered to your inbox.